Volker Wagner

Company: OranoMed

Job title: Chief Medical Officer

Seminars:

Making Successful 212Pb-Targeted Alpha Therapy a Reality 11:00 am

Seeking to develop a new generation of targeted therapies against cancer, based on the unique properties of 212Pb Exploring the multi-asset portfolio, including two compounds in clinical development and a diverse pipeline Sharing more about AlphaMedixTM receiving Breakthrough Therapy Designation by the FDARead more

day: Day Two ESC AM

Maximizing Combination Approaches to Transform Safety & Efficacy Profiles 11:00 am

Garnering excitement across the precision oncology field, combination-based approaches have proven to expand therapeutic efficacy and optimize treatment outcomes. It is no surprise that the radiopharmaceuticals space is following full steam ahead, as we see early clinical data and uncover more about the preclinical learnings in dual therapies. Discover more on combinations: Explore immune checkpoint…Read more

day: Workshop B